Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer

Page view(s)
19
Checked on Feb 03, 2024
Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer
Title:
Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer
Journal Title:
BioMed Research International
Publication Date:
29 January 2014
Citation:
Ruichuan Chen, Jasper H. N. Yik, Qiao Jing Lew, and Sheng-Hao Chao, “Brd4 and HEXIM1: Multiple Roles in P-TEFb Regulation and Cancer,” BioMed Research International, vol. 2014, Article ID 232870, 11 pages, 2014. doi:10.1155/2014/232870
Abstract:
Bromodomain-containing protein 4 (Brd4) and hexamethylene bisacetamide (HMBA) inducible protein 1 (HEXIM1) are two opposing regulators of the positive transcription elongation factor b (P-TEFb), which is the master modulator of RNA polymerase II during transcriptional elongation. While Brd4 recruits P-TEFb to promoter-proximal chromatins to activate transcription, HEXIM1 sequesters P-TEFb into an inactive complex containing the 7SK small nuclear RNA. Besides regulating P-TEFb's transcriptional activity, recent evidence demonstrates that both Brd4 and HEXIM1 also play novel roles in cell cycle progression and tumorigenesis. Here we will discuss the current knowledge on Brd4 and HEXIM1 and their implication as novel therapeutic options against cancer.
License type:
http://creativecommons.org/licenses/by/4.0/
Funding Info:
Description:
ISSN:
2314-6133
2314-6141
Files uploaded: